genome positioned upstream of said promoter;] (c) a eukaryotic splice acceptor and donor site positioned downstream of said promoter and upstream of said [gene] at least one insertion site; and (d) a polyadenylation sequence [and a portion of the adenovirus-5 genome which is suitable for homologous recombination] positioned downstream of said insertion site.

In Claim 3, line 1, please insert --adenoviral-- before "vector".

In Claim 3, line 2, please replace "the mouse" with -- a mouse--.

4. (Amended) The adenoviral vector according to Claim 1, wherein said polyadenylation sequence is the [3' processing site from the] mouse β-globin [transcription unit] polyadenylation sequence.

In Claim 9, line 1, please insert --adenoviral-- before "vector".

In Claim 17, line 1, please insert --adenoviral-- before each occurrence of "vector".

Please cancel claims 2, 7, 8, 10, 11 and 13-15.

Please add the following claims:

18. A host cell infected with the adenoviral vector of Claim 17.

19. A method for producing a selected protein, which method comprises culturing a host cell which has been infected with the adenoviral vector of Claim 17, wherein said heterologous DNA encodes a selected protein, whereupon said selected protein is produced.

Sub C3 20. A method of delivering a heterologous gene to an animal heart ~~in vivo~~, wherein the method comprises administering to the animal heart an adenoviral vector comprising (a) a heterologous gene; (b) a promoter sequence positioned upstream from the heterologous gene, the heterologous gene being under the regulatory control of the promoter; (c) a eukaryotic splice acceptor and donor site positioned